Physician profile
Mandeep Kaur
NPI 1376213793
$1,516.35
in general payments reported to CMS, 2019-2025
18 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $368 · 2023: $610 · 2024: $194 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $396.96 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $242.35 | 2023 | Aptiom, Gemtesa |
| Boston Scientific Corporation | $137.53 | 2023 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.62 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $104.08 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $97.53 | 2022-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $91.46 | 2022-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $88.25 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $41.34 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.61 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $29.93 | 2022 | |
| Dexcom, INC. | $21.65 | 2024 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $19.93 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.88 | 2025 | Alvesco |
| Pfizer INC. | $19.61 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.43 | 2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $15.83 | 2022 | |
| Exact Sciences Corporation | $14.36 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.